Direkt zum Inhalt
Merck

ω-3 intake and visual acuity in patients with retinitis pigmentosa receiving vitamin A.

Archives of ophthalmology (Chicago, Ill. : 1960) (2012-02-15)
Eliot L Berson, Bernard Rosner, Michael A Sandberg, Carol Weigel-DiFranco, Walter C Willett
ZUSAMMENFASSUNG

To evaluate whether a diet high in long chain ω-3 fatty acids can slow the rate of visual acuity loss among patients with retinitis pigmentosa receiving vitamin A palmitate. We calculated dietary intake from questionnaires completed annually by 357 adult patients from 3 randomized trials who were all receiving vitamin A, 15 000 IU/d, for 4 to 6 years. Rates of visual acuity decline were compared between those with high (≥0.20 g/d) vs low (<0.20 g/d) ω-3 intake. Analyses took age into account. Mean rates of decline of acuity were slower among those with high ω-3 intake: Early Treatment Diabetic Retinopathy Study distance acuity: high intake=0.59 letter per year, low intake=1.00 letter per year,P=.001; Snellen retinal acuity: high intake=1.5% per year, low intake=2.8% per year, P=.03. We conclude that mean annual rates of decline in distance and retinal visual acuities in adults with retinitis pigmentosa receiving vitamin A, 15 000 IU/d,are slower over 4 to 6 years among those consuming a diet rich in ω-3 fatty acids. To our knowledge, this is the first report that nutritional intake can modify the rate of decline of visual acuity in retinitis pigmentosa.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Retinylpalmitat, potency: ≥1,700,000 USP units per g
Supelco
Retinolpalmitat, analytical standard
Sigma-Aldrich
Retinylpalmitat, Type IV, ~1,800,000 USP units/g, oil
Supelco
Retinylpalmitat, Pharmaceutical Secondary Standard; Certified Reference Material